Atopic dermatitis treatment method

• US 6,838,429 B2
• Filed: 08/01/2001
• Issued: 01/04/2005
• Est. Priority Date: 10/22/1999
• Status: Expired due to Term

• Current Assignee: David A. Paslin
• Original Assignee: David A. Paslin
• Inventors: Paslin, David A.
• Primary Examiner(s): Carlson, Karen Cochrane
• Assistant Examiner(s): Robinson, Hope A.
• Application Number:
  US09/920,897
• Publication Number:
  US 20020009489A1
• Time in Patent Office: 1,252 Days
• Field of Search: 514/2, 514/12, 424/450, 604/20, 604/19, 604/290, 607/49, 530/350, 530/300
• US Class Current: 604/501
• CPC Class Codes: A61K 38/162 from virus
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

Compositions are provided for treating atopic dermatitis, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (MCV), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of MCV proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other MC148P type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other MC148P type proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100% homologous to MCV proteins so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

Claims

1. A method for treating a patient having atopic dermatitis, comprising:

administering to a patient having atopic dermatitis a therapeutically effective amount of a composition comprising a Molluscum Contagiosum viral protein (MC148P) which possesses atopic dermatitis inhibiting activity.

2. The method according to claim 1, wherein the MC148P protein is selected from the group consisting of MC148P1, MC148P2, MC148P3 and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, and MC148P3 which possess atopic dermatitis inhibiting activity.

3. The method according to claim 1, wherein administering the composition includes topically applying the composition.

4. The method according to claim 1, wherein administering the composition includes injecting the composition.

5. The method according to claim 1, wherein administering the composition includes iontophoresis.

6. The method according to claim 1, wherein administering the composition includes electroporation.

7. The method according to claim 1, wherein the composition includes a dimethyl sulfoxide carrier.

8. The method according to claim 1, wherein the composition includes an azone carrier.

9. The method according to claim 1, wherein the composition includes a liposomal carrier.

10. The method according to claim 1, wherein the composition is delivered locally to an area where atopic dermatitis is believed to be present.

11. The method according to claim 1 the composition is delivered to a patient with an atopic disease or allergic skin disorder.

19. The kit according to claim 11, wherein the composition includes a dimethyl sulfoxide carrier.

20. The kit according to claim 11, wherein the composition includes an azone carrier.

12. A kit for treating an inflammatory skin disease, comprising:

multiple separately packaged portions of a composition adapted for treating atopic dermatitis comprising a Molluscum Contagiosum Viral protein (MC148P) which possesses atopic dermatitis inhibiting activity.

13. The kit according to claim 12, wherein the MC148P is selected from the group consisting of MC148P1, MC148P2, MC148P3 and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, and MC148P3 which possess atopic dermatitis inhibiting activity.

14. The kit according to claim 12, wherein the kit further includes

instructions teaching administration of the composition to a patient having atopic dermatitis.

15. The kit according to claim 13, wherein the instructions teach locally delivering the composition to an area adjacent where atopic dermatitis is believed to be present.

16. The kit according to claim 13, wherein the instructions teach topically applying the composition.

17. The kit according to claim 13, wherein the instructions teach injecting the composition.

18. The kit according to claim 13, wherein the instructions teach administering the composition through iontophoresis and/or electroporation.